Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
  • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S424/00—Drug, bio-affecting and body treating compositions
  • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Definitions

• This invention pertains to improved methods for inducing protective immunity against Mycoplasma hyopneumoniae, specifically employing an inactivated Mycoplasma hyopneumoniae bacterin in an amount effective to immunize a recipient animal against infection by Mycoplasma hyopneumoniae in a single dose.
• Mycoplasma hyopneumoniae is the etiologic agent of swine mycoplasmal pneumonia. This disease is an important cause of economic loss in the swine industry due to reduced weight gain and poor feed efficiency. The disease causes a chronic cough, dull hair coat, retarded growth and unthrifty appearance lasting several weeks. Characteristic lesions of purple to gray areas of consolidation, particularly in ventral apical and cardiac lobes are observed in infected animals. Although the disease causes little mortality, affected swine are often prone to secondary infections by opportunistic pathogens, resulting in death or stress. Economic losses alone have been estimated at between 200 to 250 million dollars annually.
• Mycoplasma hyopneumoniae is a slow growing, fastidious bacterium which lacks a cell wall. It is frequently difficult to isolate from the respiratory tract due to Mycoplasma hyorhinis, a common secondary agent also located in the respiratory tract. The disease is spread by aerosol, produced by coughing, and by direct contact from an affected or convalescent carrier swine. Mingling of infected animals and uninfected animals results in early and frequent reinfection. Infection frequently starts with infection of piglets by carrier sows at farrowing. Due to herd management techniques, infection may not become evident until later in life. Additional infection usually is observed after weaning when pigs are pooled.
• FDAH Fort Dodge Animal Health
• FDAH Fort Dodge Animal Health
• FDAH Fort Dodge Animal Health
• FDAH markets Mycoplasma hyopneumoniae bacterin under the name Suvaxyn® Respifend® MH for use as a vaccine to protect healthy swine against clinical signs caused by Mycoplasma hyopneumoniae.
• the vaccine contains Carbopol as an adjuvant and is recommended as a two-dose vaccine for pigs at least one-week old, with the second dose two to three weeks after the first vaccination.
• a two-dose vaccine has the obvious disadvantage of requiring a second handling of the animals in order to provide full protection against disease.
• the present invention relates to a vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae comprising an immunizing amount of an inactivated Mycoplasma hyopneumoniae bacterin; an adjuvant mixture comprising an acrylic acid polymer and a mixture of a metabolizable oil and a polyoxyethylene-polyoxypropylene block copolymer; and a pharmaceutically acceptable carrier, which vaccine composition, after a single administration, elicits protective immunity from Mycoplasma hyopneumoniae.
• the present invention provides an immunogenic composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising an inactivated Mycoplasma hyopneumoniae bacterin combined with the above adjuvant mixture and a pharmaceutically acceptable stabilizer, carrier or diluent.
• the adjuvant is usually present in this vaccine composition at a final concentration of about 1-25% (v/v), and preferably about 5-12% (v/v).
• the composition may also include other vaccine components, including inactivated bacterins or purified toxoids, from one or more pathogens, such as Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis and leptospira and may be administered by intramuscular, subcutaneous, oral, aerosol or intranasal routes.
• pathogens such as Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis and leptospira
• pathogens such as Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella
• the present invention provides a method for protecting an animal against disease caused by Mycoplasma hyopneumoniae by administering a single dose of the above-vaccine comprising inactivated Mycoplasma hyopneumoniae bacterin and the adjuvant mixture.
• bacterin is a bacterium harvest which has been inactivated and which, in combination with certain adjuvants, can elicit protective immunity to protect against disease or infection when administered to animals.
• Adjuvant means a composition comprised of one or more substances that enhances the immunogencity and efficacy of Mycoplasma hyopneumoniae bacterin in a vaccine composition.
• MHDCE designates Mycoplasma Hyopneumoniae DNA cell equivalents.
• the “immunizing amount” is the amount of bacterin which will provide immunity vis a vis Mycoplasma hyopneumoniae.
• the “immunizing amount” will depend upon the species, breed, age, size, health status and whether the animal has previously been given a vaccine against the same organism.
• the present invention provides a vaccine against Mycoplasma pneumoniae that is suitable for single dose immunization.
• the vaccine of the present invention includes an adjuvant mixture that enhances the immunogenicity of the bacterin and thus provides for a single administration to elicit protective immunity.
• the vaccine may be prepared from freshly harvested cultures by methods that are standard in the art (see, for instance, U.S. Pat. No. 5,338,543 or U.S. Pat. No. 5,565,205, as well as Example 2 below). That is, the organism may be propagated in a culture medium such as PPLO (Pleuropneumonia-like organism) complete medium [Difco]. Laboratories]. The growth of the organism is monitored by standard techniques such as determining color changing units (CCU), and harvested when a sufficiently high titer has been achieved. The stocks may be further concentrated or lyophilized by conventional methods before inclusion in the vaccine for formulation. Other methods, such as those described in Thomas, et al., Agri-Practice, Vol. 7 No. 5, pp.26-30, can be employed.
• CCU color changing units
• the vaccine of the present invention comprises the inactivated Mycoplasma hyopneumoniae bacterin combined with the adjuvant mixture and one or more pharmaceutically acceptable carriers.
• Carriers suitable for use include aqueous meida, for instance, saline, phosphate-buffered saline, Minimal essential media (MEM), or MEM with HEPES buffer.
• the adjuvant mixture for use in the vaccine compositions of the present invention enhances the immune response and comprises a mixture of an acrylic acid polymer with a mixture of metabolizable oil, e.g., an unsaturated terpene hydrocarbon or a hydrogenation product thereof, preferably squalane (2,3,10,15,19,23-hexamethyltetracosane) or squalene, and a polyoxyethylene-polyoxypropylene block copolymer.
• an acrylic acid polymer may be a homopolymer or a copolymer.
• the acrylic acid polymer is preferably a carbomer.
• Carbomers are commercially available under the trade name Carbopol.
• Acrylic acid polymers are described, for example, in U.S. Pat. Nos. 2,909,462 and 3,790,665, whose disclosures are incorporated herein by reference.
• the polyoxyethylene-polyoxypropylene block copolymers are surfactants, preferably liquid surfactants, that aid in suspending solid and liquid components.
• the surfactants are commercially acailable as polymers under the trade name Pluronic®.
• the preferred surfactant is poloxamer 401 which is commercially available under the trade name Pluronic® L121.
• the immunogenically stimulating adjuvant mixture is typically present in the vaccine composition of the invention in v/v amounts of about 1% to 25%, preferably about 2% to 15%, more preferably about 5% to 12% v/v.
• the amount of adjuvant mixture use and the ratio of the two components of the adjuvant may vary depending upon the addition of other bacterins or purified toxoids.
• the adjuvant mixture generally comprises a metabolizable oil, an acrylic acid polymer and a polyoxyethylene-polyoxypropylene block copolymer formulated as an emulsion in an aqueous medium.
• the metabolizable oil and the acrylic acid polymer may be present in amounts ranging from about 10 to 150 ml/L and about 0.5 to 10 g/L, respectively.
• the mixture of the metabolizable oil and polyoxyethylene-polyoxypropylene block copolymer component is a mixture of squalane and Pluronic® L121 (poloxamer 401) which may be present in an amount of about 50 to 100 ml/L and the carboxymethylene polymer is Carbopol 934P (Carbamer 934P) which may be present in amount of about 2 ml/L.
• the adjuvant mixture contains about a 1:25 to 1:50 ratio of acrylic acid polymer to metabolizable oil/polyoxyethylene-polypropylene block copolymer mixture.
• Preferred acrylic acid polymers are those marketed by B. F Goodrich as Carbopol 934 P NF and 941 NF which are polymers of acrylic acid cross-linked with polyallylsucrose and which have the chemical formula (CH 2 CHOOOH) n . These polymers form aqueous gels which suitably formulate with aqueous carriers.
• Preferred polyoxyethylene-polypropylene block copolymers are the nonionic surfactants marketed by BASF as Pluronic® L121, L61, L,81 or L101.
• the vaccine of the present invention may be administered by intramuscular, subcutaneous, intranasal, intraperitoneal or oral routes, preferably by intramuscular or subcutaneous routes.
• the vaccine of the invention generally comprises the inactivated Mycoplasma hyopneumoniae, a metabolizable oil, a polyoxyethylene-polypropylene block copolymer and an acrylic acid polymer in the form of an oil in water emulsion.
• the vaccine preferably contains the acrylic acid polymer in a concentration within the range of 0.5 to 10 g/L.
• the vaccine preferably contains the metabolizable oil in a concentration within the range of 2 to 6 ml/L.
• the vaccine preferably contains the polyoxyethylene-propylene block copolymer in a concentration within the range of 1 to 3 ml/L.
• the vaccine should preferably contain an amount of Mycoplasma pneunomoniae bacterin corresponding to about 1 ⁇ 10 8 to 3 ⁇ 10 11 MHDCE/mL, preferably about 1 ⁇ 10 9 to 3 ⁇ 10 9 MHDCE/mL.
• About one to five mL, preferably 2 mL, may be administered per animal, intramuscularly, subcutaneously, or intraperitoneally.
• One to ten mL, preferably 2 to 5 mL, may be administered orally or intranasally.
• Mycoplasma hyopneumoniae may be obtained from any number of readily available sources.
• Mycoplasma hyopneumoniae Strain P-5722-3 may be used. The culture was obtained from C. Armstrong, Purdue University, West Lafayette, Ind. Following receipt of the Mycoplasma hyopneumoniae culture, it was passed in Mycoplasma hyopneumoniae broth seven times to establish the Master Seed.
• Mycoplasma hyopneumoniae was grown in a medium comprising Bacto PPLO Powder, yeast extract, glucose, L-cysteine hydrochloride, ampicillin, thallium acetate, phenol red, antifoam, normal sterile swine serum and water over periods ranging from 18-144 hours.
• binary ethyleneimine (BEI) is added directed to the production culture within the fermentation vessel. The pH is adjusted to 7.4, and then harvested according to conventional procedures to provide Mycoplasma hyopneumoniae bacterin.
• composition of Preservatives and Proportions Used The harvested bacterin is preserved by the addition of thimerosal and ethylene diaminete tetra-acetic acid, tetra-sodium salt (EDTA) at no more than 0.01% and 0.07%, respectively.
• EDTA tetra-sodium salt
• Ampicillin U.S.P. is present in the growth medium at 0.250 grams/liter. The concentration of residual ampicillin will vary in the final product depending on the volume of harvest fluids, with the residual ampicillin concentration in the completed product not exceeding 30 ug/mL.
• a mixture of a metabolizable oil that comprises one or more terpene hydrocarbons and a polyoxyethylene-polypropylene block copolymer, e.g., a Squalane/Pluronic L121 mixture is prepared by dissolving 10 g. sodium chloride, 0.25 g potassium chloride, 2.72 sodium phosphate dibasic, 0.25 potassium phosphate monobasic, 20 mL Pluronic L121 (BASF Corporation), 40 mL Squalane (Kodak), 3.2 mL Tween 80 in 900 mL purified water, q.s. to 1000 ml. After mixing, the ingredients may be autoclaved. The mixture is then homogenized until a stable emulsion is formed. Formalin may be added up to a final concentration of 0.2% or thimerosal may be added to a final concentration of 1:10,000.
• a Squalane/Pluronic L121 mixture is prepared by dissolving 10 g. sodium chloride, 0.25
• mice ICR female mice, six to seven weeks of age, of one consignment, from Harlan Sprague Dawley or other acceptable suppliers, are used. A minimum of 20 mice are required for immunization with each Unknown and Reference bacterin. A minimum of five mice are retained as non-inoculated controls. Test and reference bacterins are individually mixed thoroughly. Sterile, disposable syringes, fitted with 25-gauge by 5 ⁇ 8 inch needles, are used to inoculate the mice subcutaneously in the inguinal region with 1/10 th of a host animal dose (0.2 mL). Each group of mice is housed as an individual unit and allowed free access to food and water for 14 days. Each mouse is then anesthetized.
• the anesthetized mouse is placed on its back. Using one hand, the head is held down and one front leg is extended away from the body. Using a scalpel, a skin incision is made approximately 1 ⁇ 2-inch long between the extended front leg and thorax, severing the brachial artery. Using a 3.0 mL syringe, without needle, the blood which is pooled in the incision, is collected. The blood discharged into a labeled test tube and is allowed to clot. The clotted tubes are centrifuged at 1,000 ⁇ g to separate the serum from the clot. Individual serums are stored at ⁇ 20° C. or colder until tested.
• SEROLOGICAL TESTING An ELISA Procedure is used to measure the antibody response of mice to the Reference and/or Unknown bacterins.
• the ELISA Procedure is conducted using Disposable Immulon II Flat-Bottom Microtiter Plates from Dynatech or equivalent and an ELISA Plate Reader.
• Phosphate Buffered Saline-Tween (PBST) (pH adjusted to 7.2 to 7.4 with 5N NaOH or 5N HCl). Amount Per Liter Ingredients Liter NaCl 8.50 grams NaH 2 PO 4 0.22 grams Na 2 HPO 4 1.19 grams Tween-20 0.50 ml Deionized Water q.s. 1,000.00 ml
• Glycine Buffered Saline (GBS) (pH adjusted to 9.5 to 9.7 with 5N NaOH or 5N HCl). Ingredients Amount Per Liter Glycine 0.75 grams NaCl 8.50 grams Deionized Water q.s. 1,000.00 ml
• Positive Control Serum is a pool of serums from mice vaccinated with Mycoplasma hyopneumoniae bacterin.
• Affinity-Purified Anti-Mouse IgG Peroxidase-Labeled conjugate is obtained from Kirkegaard and Perry Laboratories, Inc. (Catalog No. 074-1802). The procedure for determining the optimal dilution of conjugate is detailed below.
• the Peroxidase Substrate Solutions (ABTS) are obtained from Kirkegaard and Perry, Inc.
• Titration of Conjugate An Immulon II Flat-Bottom Plate is coated with 100 ul per well of 20 ug per mL Mycoplasma hyopneumoniae Whole Cell Antigen diluted in 10 mM GBS. The plate is incubated for no less than one hour at 37° C.+2° C.
• PBST Prior to using the plate is washed three times with PBST, with a one-minute soaking time between each wash, and is tapped to dry.
• a 1:40 dilution in PBST of the Positive Control Serum is prepared, and the diluted Positive Serum (100 uL/well) is added to one-half of the wells in the plate.
• PBST is added to the other one-half of the wells.
• the plate is incubated for one hour at room temperature, after which the plate is washed three times.
• the conjugated serum is serially diluted with PBST two-fold, starting with a 1:100 dilution and ending with a 1:10,240 dilution.
• each conjugate dilution is added to four wells of the Positive Serum and four wells of the PBST, and is allowed to react for one-half hour at room temperature.
• the plates are washed four times, and 100 ul of the Peroxidase Substrate Solution (abts) is added per well.
• a dilution of Conjugate is chosen that gives a reading of 0.850 to 1.050 for the Positive Control Serum when the value of the PBST Control is subtracted from the value of the Positive Control Serum.
• Test Antigen [0046]
• Mycoplasma hyopneumoniae Antigen is a whole cell preparation, and is supplied by Fort Dodge Animal Health.
• the ELISA is performed as follows: Dynatech Immulon II Flat-Bottom Microtiter Plates are used.
• One vial of Lyophilized Mycoplasma hyopneumoniae Whole Cell Antigen is reconstituted to ten ml with Glycine Buffered Saline (GBS).
• GBS Glycine Buffered Saline
• the concentration of the reconstituted Mycoplasma Protein is 20 ⁇ g/mL.
• 100 ⁇ l (2 ⁇ g) of diluted antigen is then added to all wells of a plate. The plate is incubated at 37° C. ⁇ 2° C. for no less than one hour and then transferred to 2-7° C. for a minimum of 18 hours and a maximum of one week.
• the plates are washed three times with PBST, soaking one minute between each wash, and are then tapped dry. Serums are diluted 1:40 in PBST. The Positive Control Serum will be included in quadruplicate on every plate. Sample volume per well is 100 ⁇ l. Serial Test Serum Samples and Reference Serum Samples will be tested in duplicate on the same plate. The plates are incubated for one hour at room temperature, and are washed three times with PBST. 100 ⁇ l of Anti-Mouse IgG Peroxidase-Labeled Conjugate (Kirkegaard and Perry), diluted in PBST is added to all wells, and the wells are incubated for 30 minutes at room temperature. The plates are washed four times with PBST.
• ABTS Peroxidase Substrate Solution
• the Mean Values for the Serial Vaccinates, the Reference Vaccinates, and the Controls are calculated and evaluated as follows: To be considered satisfactory, the Test Bacterin must demonstrate an average Mean Optical Density Value equal to, or greater than, the Reference. Or, using a One-Tailed Student's T-Test, the Test Bacterin must not be significantly (p ⁇ 0.05 Confidence Level) lower than the Reference Bacterin. Any calculated T-Value equal to, or greater than, 1.686 will indicate a significant difference between the Reference and Test Bacterin, and will cause the Test Bacterin to be rejected. Any calculated T-Value less than 1.686 will indicate a satisfactory serial. Any test bacterin determined by the Test to be unsatisfactory for any reason unrelated to product efficacy is re-tested, and the initial test is regarded as invalid.
• the vaccine for testing was prepared according to the procedures detailed in Example 1 using 5% of a mixture of a metabolizable oil that comprises one or more terpene hydrocarbons and a polyoxyethylene-polypropylene block copolymer (Squalane/Pluronic L121 mixture) and 0.2% acrylic acid polymer (Carbopol) as adjuvant, and 2 ⁇ 10 9 M. hyopneumoniae DNA cell equivalents (MHDCE) per dose.
• a mixture of a metabolizable oil that comprises one or more terpene hydrocarbons and a polyoxyethylene-polypropylene block copolymer (Squalane/Pluronic L121 mixture) and 0.2% acrylic acid polymer (Carbopol) as adjuvant, and 2 ⁇ 10 9 M. hyopneumoniae DNA cell equivalents (MHDCE) per dose.
• MHDCE hyopneumoniae DNA cell equivalents
• This study was designed to demonstrate four months duration of immunity (DOI) in pigs induced by one-dose vaccination of the vaccine of Example 2 at an age of three weeks.
• Example 2 a vaccine of Example 2 was evaluated together with a commercially available product, Ingelvac M. hyo® manufactured by Boehringer Ingelheim (BI), by a high level of virulent M. hyopneumoniae (0.4 ⁇ 10 6 organisms) challenge.
• Twenty-two (22) pigs at the age of 18-21 days were vaccinated with the vaccine of Example 2 intramuscularly (IM) and eight (8) pigs with the Ingelvac M. hyo® [serial 271 032].
• Twenty-two (22) pigs served as challenge controls and 10 pigs as non-challenge controls.
• the pigs in the vaccinated and challenge control groups were challenged with virulent M.
• the pigs vaccinated with the vaccine of Example 2 had average lung lesions of 15.9% and the challenged control pigs had average lung lesions of 19.6%.
• ISU Iowa State University
• the vaccine of Example 2 induces protective immunity against the virulent M. hyopneumoniae challenge at four months after one-dose vaccination in pigs at the age of three weeks.
• pigs Five pigs (two pigs vaccinated with the vaccine of Example 2, one with the BI vaccine and two controls) died during the vaccination holding period due to reasons not related to the vaccination.
• the remaining pigs in the vaccinated groups and challenge control group were challenged with 14 mL of virulent M. hyopneumoniae (1.4 ⁇ 10 6 organisms) at four months after the vaccination.
• the pigs in all four groups were euthanized 30 days after the challenge and lung lesions were scored for each pig in the trial.
• Each pig in the vaccination groups was given one 2 mL dose of the test vaccines IM in the side of the neck.
• the virulent M. hyopneumoniae challenge stock, a frozen ( ⁇ 70° C.) lung homogenate was prepared by Dr. Eileen Thacker from Iowa State University (ISU).
• the challenge stock was confirmed to be pure and contained approximately 10 7 M. hyopneumoniae organisms per mL.
• the recommended challenge dose is 10 mL of a 1:100 diluted stock (i.e., 1.0 ⁇ 10 6 organisms).
• the pigs in the vaccinated and challenge control groups in the first trial were challenged with 14 ml of 1:100 diluted stock (i.e. 1.4 ⁇ 10 6 organisms).
• the pigs in the second trial were challenged with 10 mL of 1:100 diluted stock (i.e., 1.0 ⁇ 10 6 organisms) as recommended.
• Lung lesion scores were compared between vaccinated and non-vaccinated groups by analysis of variance (ANOVA). Lung scores were arcsine transformed to improve the distribution of the residuals.
• the first trial was conducted to determine if the vaccine of Example 2 could stimulate strong immunity which could protect against a higher level of challenge than that recommended by ISU at four months after the vaccination. This trial also compared a vaccine of Example 2 with the commercially available, Ingelvac M. hyo®, for its ability to stimulate protective immunity at four months after vaccination.
• the pigs in the vaccinated and challenge control groups in trial two were evaluated with the challenge dose (1.0 ⁇ 10 6 organisms) as recommended by ISU at four months after vaccination to demonstrate four months DOI.
• the percentages of lung lesion are summarized in Table 3.
• the control group had an average lung lesion of 10.4%.
• the vaccinated group had the average lung lesion of 5.5%.
• There is a significant difference between the vaccinated and the control groups (p 0.031). This indicates that the vaccine of Example 2 is efficacious in stimulating protective immunity, which can last at least four months after a single dose vaccination in pigs at the age of three weeks.
• test vaccine A was prepared.
• Test Vaccine A Amounts for 1,000,000 doses (2 mL each): % vol/vol Mycoplasma Concentrate (>1.0 ⁇ 10 10 1200,000 mL 60.0 MHDCE/ml) Squalane/Pluronic L121 mixture 200,000 mL 10.0 Carbopol (2% w/v in water) 200,000 mL 10.0 Thimerosal Solution 1% w/v in water 18,000 mL 0.9 and EDTA (tetrasodium salt) 7 w/v % Sterile Saline 382,000 mL 19.1
• Each pig in the vaccination groups was given one 2 mL-dose of the test vaccine IM in the side of the neck.
• the virulent M. hyopneumoniae challenge stock a frozen ( ⁇ 70° C.) lung homogenate, was prepared by Dr. Eileen Thacker from Iowa State University (ISU). The challenge stock was confirmed to be pure and contained approximately 10 7 M. hyopneumoniae organisms per mL.
• the pigs were challenged with 10 mL of a 1:100 dilution of the stock (i.e., approximately 1.0 ⁇ 10 6 organisms).
• Lung lesion scores were compared between vaccinates and controls by one-way ANOVA.
• the lung lesion scores were arc sine transformed to improve the distribution of the residuals. Since the normality assumption for the lung lesion scores was questionable, both the lung lesion scores and the arc sine transformed lung lesion scores were analyzed by Wilcoxon Rank Sum test. The level of significance was set at p ⁇ 0.05. The results from the non-parametric, Wilcoxon Rank Sum test were used for reporting purposes.
• All pigs were tested for serum antibodies against M. hyopneumoniae by a commercial competitive ELISA kit, using a 1:10 serum dilution for all testing. The samples with test result suspicious per kit instructions are treated as positive in data analysis. All pigs were sero-negative (antibody titer ⁇ 10) at the time of vaccination, indicating the animals were susceptible to M. hyopneumoniae. All pigs in the control groups remained sero-negative before challenge. After vaccination, fifteen of twenty vaccinates (15/20) became sero-positive to M. hyopneumoniae at least once (samples collected at 35 DPV and ⁇ 1 DPC).
• Test Vaccine A induces protective immunity against a virulent M. hyopneumonia challenge for six months after a single dose administration in pigs vaccinated at the age of three weeks.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=22972978

Family Applications (4)

Family Applications After (3)

Country Status (28)

Cited By (1)

Families Citing this family (34)

Citations (6)

Family Cites Families (24)

• 2001
  • 2001-11-27 MY MYPI20015418A patent/MY129765A/en unknown
  • 2001-12-11 AT AT01990123T patent/ATE359813T1/de active
  • 2001-12-11 RS YUP-493/03A patent/RS51536B/sr unknown
  • 2001-12-11 CZ CZ2003-1721A patent/CZ307075B6/cs not_active IP Right Cessation
  • 2001-12-11 WO PCT/US2001/047865 patent/WO2002049666A2/en active IP Right Grant
  • 2001-12-11 AU AU2899302A patent/AU2899302A/xx active Pending
  • 2001-12-11 NZ NZ526904A patent/NZ526904A/en not_active IP Right Cessation
  • 2001-12-11 EP EP01990123A patent/EP1343525B1/de not_active Expired - Lifetime
  • 2001-12-11 DK DK01990123T patent/DK1343525T3/da active
  • 2001-12-11 MX MXPA03005357A patent/MXPA03005357A/es active IP Right Grant
  • 2001-12-11 HU HU0400687A patent/HU227431B1/hu unknown
  • 2001-12-11 JP JP2002551004A patent/JP5074656B2/ja not_active Expired - Lifetime
  • 2001-12-11 BR BRPI0116249A patent/BRPI0116249B1/pt active IP Right Grant
  • 2001-12-11 KR KR1020037008293A patent/KR100874119B1/ko active IP Right Grant
  • 2001-12-11 PT PT01990123T patent/PT1343525E/pt unknown
  • 2001-12-11 ES ES01990123T patent/ES2283452T3/es not_active Expired - Lifetime
  • 2001-12-11 CN CNB018226345A patent/CN1296095C/zh not_active Expired - Lifetime
  • 2001-12-11 ME MEP-859/08A patent/ME00570A/xx unknown
  • 2001-12-11 PL PL363220A patent/PL211174B1/pl unknown
  • 2001-12-11 AU AU2002228993A patent/AU2002228993B2/en not_active Expired
  • 2001-12-11 DE DE60127994T patent/DE60127994T2/de not_active Expired - Lifetime
  • 2001-12-14 TW TW090131039A patent/TWI308872B/zh not_active IP Right Cessation
  • 2001-12-18 AR ARP010105861A patent/AR033410A1/es not_active Application Discontinuation
• 2002
  • 2002-01-08 US US10/039,383 patent/US20020131980A1/en not_active Abandoned
• 2003
  • 2003-06-11 BG BG107898A patent/BG66213B1/bg unknown
  • 2003-07-17 ZA ZA200305545A patent/ZA200305545B/en unknown
  • 2003-07-18 HR HR20030585A patent/HRP20030585B1/xx not_active IP Right Cessation
  • 2003-12-09 HK HK03108934A patent/HK1056513A1/xx not_active IP Right Cessation
• 2006
  • 2006-08-21 US US11/507,231 patent/US7666439B2/en not_active Expired - Lifetime
• 2007
  • 2007-06-21 CY CY20071100827T patent/CY1106669T1/el unknown
• 2008
  • 2008-11-13 JP JP2008291001A patent/JP2009073855A/ja active Pending
• 2010
  • 2010-01-22 US US12/692,275 patent/US8187588B2/en not_active Expired - Lifetime
• 2012
  • 2012-04-27 US US13/458,541 patent/US9238065B2/en not_active Expired - Fee Related

Patent Citations (6)

Also Published As

Similar Documents

Legal Events